Hansoh Pharmaceutical Group Co. Ltd. has released its 2024 annual report, detailing significant progress in drug research and development and operational excellence. The company reported that revenue from innovative drugs and collaborative products reached approximately 9,477 million, representing about 77.3% of the total revenue. The report highlights the company's strategic focus on innovation and internationalization, reinforced through international licensing collaborations. Furthermore, Hansoh Pharma maintained its AA rating in the MSCI ESG rating and ranked first in the Chinese pharmaceutical industry in the 2024 S&P Global Corporate Sustainability Assessment. The full report can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on April 28, 2025, and is solely responsible for the information contained therein.